乳腺癌患者的PET/CT:临床影响体现在哪里
本文综述FDG PET/CT在乳腺癌初始分期、治疗反应评估和疑似复发评估中的作用,讨论其在原发乳腺病灶、腋窝及腋外淋巴结转移和远处转移分期中的优势与不足,并比较其与其他影像方法评估治疗反应的价值,同时回顾美国国家综合癌症网络指南的相关推荐。
要点
- FDG PET/CT影响乳腺癌患者的初始分期、治疗反应评估及疑似复发评估。
- 文章评述FDG PET/CT在原发灶、腋窝及腋外淋巴结和远处转移分期中的优势与不足。
- 肿瘤组织学类型可能影响PET/CT判读,文章对此进行了讨论。
核心结论
- 尽管FDG PET/CT是目前对乳腺癌患者临床管理影响最大的PET检查方式,新型放射性示踪剂和成像系统仍在不断拓宽PET在乳腺癌患者中的应用。
- 文章回顾了美国国家综合癌症网络指南中关于FDG PET/CT用于乳腺癌患者的推荐,并重点阐述FDG PET/CT已显示临床效果之处。
研究设计与样本
- 综述,回顾FDG PET/CT在乳腺癌分期、治疗反应评估和疑似复发评估中的优势与不足,并比较其与其他影像方法评估治疗反应的价值。
临床应用与阅片要点
- 文章回顾美国国家综合癌症网络指南中关于FDG PET/CT用于乳腺癌患者的推荐,并重点阐述FDG PET/CT已显示临床效果之处。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple settings, including initial staging, treatment response assessment, and evaluation of suspected recurrence. This article reviews the strengths and weaknesses of FDG PET/CT for the staging of the primary breast lesion, axillary and extraaxillary nodal metastases, and distant metastases. The utility of FDG PET/CT for measuring breast cancer treatment response is appraised and compared with other imaging modalities. The role that tumor histologic type may have on PET/CT interpretation is also discussed. CONCLUSION. Although FDG PET/CT is currently the PET modality with the greatest effect on clinical management of patients with breast cancer, novel radiotracers and imaging systems continue to broaden the application of PET for patients with breast cancer. National Comprehensive Cancer Network guidelines for FDG PET/CT for patients with breast cancer are reviewed. Emphasis is given where FDG PET/CT has shown clinical effect.
引用
- Ulaner GA. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? AJR Am J Roentgenol. 2019. PMID: 31063423. doi:10.2214/AJR.19.21177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。